pCDNA5-LRRK2 Citations (1)

Originally described in: A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2.
Dederer V, Sanz Murillo M, Karasmanis EP, Hatch KS, Chatterjee D, Preuss F, Abdul Azeez KR, Nguyen LV, Galicia C, Dreier B, Pluckthun A, Versees W, Mathea S, Leschziner AE, Reck-Peterson SL, Knapp S J Biol Chem. 2024 Jul;300(7):107469. doi: 10.1016/j.jbc.2024.107469. Epub 2024 Jun 12. PubMed Journal

---

Articles Citing pCDNA5-LRRK2

Articles
Type II kinase inhibitors that target Parkinson's disease-associated LRRK2. Raig ND, Surridge KJ, Sanz-Murillo M, Dederer V, Kramer A, Schwalm MP, Lattal NM, Elson L, Chatterjee D, Mathea S, Hanke T, Leschziner AE, Reck-Peterson SL, Knapp S. Sci Adv. 2025 Jun 6;11(23):eadt2050. doi: 10.1126/sciadv.adt2050. Epub 2025 Jun 4. PubMed

If you have published an article using this material, please email us at to have your article added to this page.